Y-box binding protein 1 - A prognostic marker and target in tumour therapy

European Journal of Cell Biology

Volumn 93, Issue 1-2, 2014, Pages 61-70

  Kosnopfel, Corinna ^a   Sinnberg, Tobias ^a   Schittek, Birgit ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Angiogenesis; Chemoresistance; DNA repair; Genomic instability; Migration invasion; Oncogene; Proliferation; Survival; Transcription factor; Translational regulation

Indexed keywords

Y BOX BINDING PROTEIN 1; ANTINEOPLASTIC AGENT; TUMOR MARKER;

BLADDER CANCER; BREAST CANCER; CANCER PROGNOSIS; CANCER THERAPY; CANCER TISSUE; CELL NUCLEUS; CELLULAR DISTRIBUTION; COLORECTAL CARCINOMA; CYTOPLASM; DISEASE MARKER; DRUG TARGETING; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; KIDNEY CANCER; LARGE CELL LYMPHOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; MULTIPLE MYELOMA; NASOPHARYNX CANCER; NEOPLASM; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; REGULATORY MECHANISM; RHABDOMYOSARCOMA; SHORT SURVEY; STOMACH CANCER; THYROID TUMOR; UTERINE CERVIX CANCER; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PROGNOSIS; SKIN NEOPLASMS;

ANTINEOPLASTIC AGENTS; CELL NUCLEUS; HUMANS; MELANOMA; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROGNOSIS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; Y-BOX-BINDING PROTEIN 1;

EID: 84897478180     PISSN: 01719335     EISSN: 16181298     Source Type: Journal    
DOI: 10.1016/j.ejcb.2013.11.007     Document Type: Short Survey

References (122)

1. Astanehe A., Finkbeiner M.R., Hojabrpour P., To K., Fotovati A., Shadeo A., Stratford A.L., Lam W.L., Berquin I.M., Duronio V., Dunn S.E. The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1. Oncogene 2009, 28:2406-2418.
2. Bader A.G., Felts K.A., Jiang N., Chang H.W., Vogt P.K. Y box-binding protein 1 induces resistance to oncogenic transformation by the phosphatidylinositol 3-kinase pathway. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:12384-12389.
3. Bader A.G., Vogt P.K. Phosphorylation by Akt disables the anti-oncogenic activity of YB-1. Oncogene 2008, 27:1179-1182.
4. Bargou R.C., Jurchott K., Wagener C., Bergmann S., Metzner S., Bommert K., Mapara M.Y., Winzer K.J., Dietel M., Dorken B., Royer H.D. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat. Med. 1997, 3:447-450.
5. Basaki Y., Hosoi F., Oda Y., Fotovati A., Maruyama Y., Oie S., Ono M., Izumi H., Kohno K., Sakai K., Shimoyama T., Nishio K., Kuwano M. Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells. Oncogene 2007, 26:2736-2746.
6. Bommert K.S., Effenberger M., Leich E., Kuspert M., Murphy D., Langer C., Moll R., Janz S., Mottok A., Weissbach S., Rosenwald A., Bargou R., Bommert K. The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival. Leukemia 2013, 27:441-450.
7. Brandt S., Raffetseder U., Djudjaj S., Schreiter A., Kadereit B., Michele M., Pabst M., Zhu C., Mertens P.R. Cold shock Y-box protein-1 participates in signaling circuits with auto-regulatory activities. Eur. J. Cell Biol. 2012, 91:464-471.
8. Chatterjee M., Rancso C., Stuhmer T., Eckstein N., Andrulis M., Gerecke C., Lorentz H., Royer H.D., Bargou R.C. The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma. Blood 2008, 111:3714-3722.
9. Cobbold L.C., Spriggs K.A., Haines S.J., Dobbyn H.C., Hayes C., de Moor C.H., Lilley K.S., Bushell M., Willis A.E. Identification of internal ribosome entry segment (IRES)-trans-acting factors for the Myc family of IRESs. Mol. Cell. Biol. 2008, 28:40-49.
10. Cohen S.B., Ma W., Valova V.A., Algie M., Harfoot R., Woolley A.G., Robinson P.J., Braithwaite A.W. Genotoxic stress-induced nuclear localization of oncoprotein YB-1 in the absence of proteolytic processing. Oncogene 2010, 29:403-410.
11. Coles L.S., Lambrusco L., Burrows J., Hunter J., Diamond P., Bert A.G., Vadas M.A., Goodall G.J. Phosphorylation of cold shock domain/Y-box proteins by ERK2 and GSK3beta and repression of the human VEGF promoter. FEBS Lett. 2005, 579:5372-5378.
12. Dahl E., En-Nia A., Wiesmann F., Krings R., Djudjaj S., Breuer E., Fuchs T., Wild P.J., Hartmann A., Dunn S.E., Mertens P.R. Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer. BMC Cancer 2009, 9:410.
13. Das S., Chattopadhyay R., Bhakat K.K., Boldogh I., Kohno K., Prasad R., Wilson S.H., Hazra T.K. Stimulation of NEIL2-mediated oxidized base excision repair via YB-1 interaction during oxidative stress. J. Biol. Chem. 2007, 282:28474-28484.
14. Davies A.H., Barrett I., Pambid M.R., Hu K., Stratford A.L., Freeman S., Berquin I.M., Pelech S., Hieter P., Maxwell C., Dunn S.E. YB-1 evokes susceptibility to cancer through cytokinesis failure, mitotic dysfunction and HER2 amplification. Oncogene 2011, 30:3649-3660.
15. Didier D.K., Schiffenbauer J., Woulfe S.L., Zacheis M., Schwartz B.D. Characterization of the cDNA encoding a protein binding to the major histocompatibility complex class II Y box. Proc. Natl. Acad. Sci. U.S.A. 1988, 85:7322-7326.
16. Dolfini D., Mantovani R. Targeting the Y/CCAAT box in cancer: YB-1 (YBX1) or NF-Y?. Cell Death Differ. 2013, 20:676-685.
17. Dolfini D., Mantovani R. YB-1 (YBX1) does not bind to Y/CCAAT boxes in vivo. Oncogene 2013, 32:4189-4190.
18. Dutertre M., Sanchez G., De Cian M.C., Barbier J., Dardenne E., Gratadou L., Dujardin G., Le Jossic-Corcos C., Corcos L., Auboeuf D. Cotranscriptional exon skipping in the genotoxic stress response. Nat. Struct. Mol. Biol. 2010, 17:1358-1366.
19. Eliseeva I.A., Kim E.R., Guryanov S.G., Ovchinnikov L.P., Lyabin D.N. Y-box-binding protein 1 (YB-1) and its functions. Biochemistry (Mosc.) 2011, 76:1402-1433.
20. Evdokimova V., Ovchinnikov L.P., Sorensen P.H. Y-box binding protein 1: providing a new angle on translational regulation. Cell Cycle 2006, 5:1143-1147.
21. Evdokimova V., Ruzanov P., Anglesio M.S., Sorokin A.V., Ovchinnikov L.P., Buckley J., Triche T.J., Sonenberg N., Sorensen P.H. Akt-mediated YB-1 phosphorylation activates translation of silent mRNA species. Mol. Cell. Biol. 2006, 26:277-292.
22. Evdokimova V., Ruzanov P., Imataka H., Raught B., Svitkin Y., Ovchinnikov L.P., Sonenberg N. The major mRNA-associated protein YB-1 is a potent 5' cap-dependent mRNA stabilizer. EMBO J. 2001, 20:5491-5502.
23. Evdokimova V., Tognon C., Ng T., Ruzanov P., Melnyk N., Fink D., Sorokin A., Ovchinnikov L.P., Davicioni E., Triche T.J., Sorensen P.H. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell 2009, 15:402-415.
24. Evdokimova V.M., Kovrigina E.A., Nashchekin D.V., Davydova E.K., Hershey J.W., Ovchinnikov L.P. The major core protein of messenger ribonucleoprotein particles (p50) promotes initiation of protein biosynthesis in vitro. J. Biol. Chem. 1998, 273:3574-3581.
25. Evdokimova V.M., Wei C.L., Sitikov A.S., Simonenko P.N., Lazarev O.A., Vasilenko K.S., Ustinov V.A., Hershey J.W., Ovchinnikov L.P. The major protein of messenger ribonucleoprotein particles in somatic cells is a member of the Y-box binding transcription factor family. J. Biol. Chem. 1995, 270:3186-3192.
26. Faury D., Nantel A., Dunn S.E., Guiot M.C., Haque T., Hauser P., Garami M., Bognar L., Hanzely Z., Liberski P.P., Lopez-Aguilar E., Valera E.T., Tone L.G., Carret A.S., Del Maestro R.F., Gleave M., Montes J.L., Pietsch T., Albrecht S., Jabado N. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J. Clin. Oncol. 2007, 25:1196-1208.
27. Fenouille N., Tichet M., Dufies M., Pottier A., Mogha A., Soo J.K., Rocchi S., Mallavialle A., Galibert M.D., Khammari A., Lacour J.P., Ballotti R., Deckert M., Tartare-Deckert S. The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion. PLoS ONE 2012, 7:e40378.
28. Frye B.C., Halfter S., Djudjaj S., Muehlenberg P., Weber S., Raffetseder U., En-Nia A., Knott H., Baron J.M., Dooley S., Bernhagen J., Mertens P.R. Y-box protein-1 is actively secreted through a non-classical pathway and acts as an extracellular mitogen. EMBO Rep. 2009, 10:783-789.
29. Fujiwara-Okada Y., Matsumoto Y., Fukushi J., Setsu N., Matsuura S., Kamura S., Fujiwara T., Iida K., Hatano M., Nabeshima A., Yamada H., Ono M., Oda Y., Iwamoto Y. Y-box binding protein-1 regulates cell proliferation and is associated with clinical outcomes of osteosarcoma. Br. J. Cancer 2013, 108:836-847.
30. Fushimi F., Taguchi K., Izumi H., Kohno K., Kuwano M., Ono M., Nakashima Y., Takesue T., Naito S., Oda Y. Peroxiredoxins, thioredoxin, and Y-box-binding protein-1 are involved in the pathogenesis and progression of dialysis-associated renal cell carcinoma. Virchows Arch. 2013, 463:553-562.
31. Gaudreault I., Guay D., Lebel M. YB-1 promotes strand separation in vitro of duplex DNA containing either mispaired bases or cisplatin modifications, exhibits endonucleolytic activities and binds several DNA repair proteins. Nucleic Acids Res. 2004, 32:316-327.
32. Gessner C., Woischwill C., Schumacher A., Liebers U., Kuhn H., Stiehl P., Jurchott K., Royer H.D., Witt C., Wolff G. Nuclear YB-1 expression as a negative prognostic marker in nonsmall cell lung cancer. Eur. Respir. J. 2004, 23:14-19.
33. Gimenez-Bonafe P., Fedoruk M.N., Whitmore T.G., Akbari M., Ralph J.L., Ettinger S., Gleave M.E., Nelson C.C. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate 2004, 59:337-349.
34. Gluz O., Mengele K., Schmitt M., Kates R., Diallo-Danebrock R., Neff F., Royer H.D., Eckstein N., Mohrmann S., Ting E., Kiechle M., Poremba C., Nitz U., Harbeck N. Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy. J. Clin. Oncol. 2009, 27:6144-6151.
35. Grant C.E., Deeley R.G. Cloning and characterization of chicken YB-1: regulation of expression in the liver. Mol. Cell. Biol. 1993, 13:4186-4196.
36. Habibi G., Leung S., Law J.H., Gelmon K., Masoudi H., Turbin D., Pollak M., Nielsen T.O., Huntsman D., Dunn S.E. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res. 2008, 10:R86.
37. Hanssen L., Alidousty C., Djudjaj S., Frye B.C., Rauen T., Boor P., Mertens P.R., van Roeyen C.R., Tacke F., Heymann F., Tittel A.P., Koch A., Floege J., Ostendorf T., Raffetseder U. YB-1 is an early and central mediator of bacterial and sterile inflammation in vivo. J. Immunol. 2013, 191:2604-2613.
38. Hanzawa K., Momose S., Higashi M., Tokuhira M., Watanabe R., Kajino K., Hino O., Itoyama S., Kizaki M., Tamaru J. Y-box binding protein-1 expression in diffuse large B-cell lymphoma: an impact on prognosis in the rituximab era. Leuk. Lymphoma 2010, 51:2054-2062.
39. Haruki N., Kawaguchi K.S., Eichenberger S., Massion P.P., Olson S., Gonzalez A., Carbone D.P., Dang T.P. Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers. Cancer Res. 2005, 65:3555-3561.
40. Hasegawa S.L., Doetsch P.W., Hamilton K.K., Martin A.M., Okenquist S.A., Lenz J., Boss J.M. DNA binding properties of YB-1 and dbpA: binding to double-stranded, single-stranded, and abasic site containing DNAs. Nucleic Acids Res. 1991, 19:4915-4920.
41. Holm P.S., Bergmann S., Jurchott K., Lage H., Brand K., Ladhoff A., Mantwill K., Curiel D.T., Dobbelstein M., Dietel M., Gansbacher B., Royer H.D. YB-1 relocates to the nucleus in adenovirus-infected cells and facilitates viral replication by inducing E2 gene expression through the E2 late promoter. J. Biol. Chem. 2002, 277:10427-10434.
42. Holm P.S., Lage H., Bergmann S., Jurchott K., Glockzin G., Bernshausen A., Mantwill K., Ladhoff A., Wichert A., Mymryk J.S., Ritter T., Dietel M., Gansbacher B., Royer H.D. Multidrug-resistant cancer cells facilitate E1-independent adenoviral replication: impact for cancer gene therapy. Cancer Res. 2004, 64:322-328.
43. Holzmuller R., Mantwill K., Haczek C., Rognoni E., Anton M., Kasajima A., Weichert W., Treue D., Lage H., Schuster T., Schlegel J., Gansbacher B., Holm P.S. YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma. Int. J. Cancer 2011, 129:1265-1276.
44. Homer C., Knight D.A., Hananeia L., Sheard P., Risk J., Lasham A., Royds J.A., Braithwaite A.W. Y-box factor YB1 controls p53 apoptotic function. Oncogene 2005, 24:8314-8325.
45. Hsieh A.C., Liu Y., Edlind M.P., Ingolia N.T., Janes M.R., Sher A., Shi E.Y., Stumpf C.R., Christensen C., Bonham M.J., Wang S., Ren P., Martin M., Jessen K., Feldman M.E., Weissman J.S., Shokat K.M., Rommel C., Ruggero D. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012, 485:55-61.
46. Ise T., Nagatani G., Imamura T., Kato K., Takano H., Nomoto M., Izumi H., Ohmori H., Okamoto T., Ohga T., Uchiumi T., Kuwano M., Kohno K. Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. Cancer Res. 1999, 59:342-346.
47. Ito K., Tsutsumi K., Kuzumaki T., Gomez P.F., Otsu K., Ishikawa K. A novel growth-inducible gene that encodes a protein with a conserved cold-shock domain. Nucleic Acids Res. 1994, 22:2036-2041.
48. Ito Y., Yoshida H., Shibahara K., Uruno T., Nakano K., Takamura Y., Miya A., Kobayashi K., Yokozawa T., Matsuzuka F., Uchimi T., Kuwano M., Miyoshi E., Matsuura N., Kuma K., Miyauchi A. Y-box binding protein expression in thyroid neoplasms: its linkage with anaplastic transformation. Pathol. Int. 2003, 53:429-433.
49. Janz M., Harbeck N., Dettmar P., Berger U., Schmidt A., Jurchott K., Schmitt M., Royer H.D. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int. J. Cancer 2002, 97:278-282.
50. Jonquières G.v. Funktionelle Analyse von YB-1 Interaktionen 2008, (PhD thesis), University of Bonn, Universitäts- und Landesbibliothek Bonn.
51. Jurchott K., Bergmann S., Stein U., Walther W., Janz M., Manni I., Piaggio G., Fietze E., Dietel M., Royer H.D. YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression. J. Biol. Chem. 2003, 278:27988-27996.
52. Kamura T., Yahata H., Amada S., Ogawa S., Sonoda T., Kobayashi H., Mitsumoto M., Kohno K., Kuwano M., Nakano H. Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma?. Cancer 1999, 85:2450-2454.
53. Kang Y., Hu W., Ivan C., Dalton H.J., Miyake T., Pecot C.V., Zand B., Liu T., Huang J., Jennings N.B., Rupaimoole R., Taylor M., Pradeep S., Wu S.Y., Lu C., Wen Y., Huang J., Liu J., Sood A.K. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J. Natl. Cancer Inst. 2013, 105:1485-1495.
54. Kaszubiak A., Kupstat A., Muller U., Hausmann R., Holm P.S., Lage H. Regulation of MDR1 gene expression in multidrug-resistant cancer cells is independent from YB-1. Biochem. Biophys. Res. Commun. 2007, 357:295-301.
55. Koike K., Uchiumi T., Ohga T., Toh S., Wada M., Kohno K., Kuwano M. Nuclear translocation of the Y-box binding protein by ultraviolet irradiation. FEBS Lett. 1997, 417:390-394.
56. Kolk A., Jubitz N., Mengele K., Mantwill K., Bissinger O., Schmitt M., Kremer M., Holm P.S. Expression of Y-box-binding protein YB-1 allows stratification into long- and short-term survivors of head and neck cancer patients. Br. J. Cancer 2011, 105:1864-1873.
57. Kolluri R., Torrey T.A., Kinniburgh A.J. A CT promoter element binding protein: definition of a double-strand and a novel single-strand DNA binding motif. Nucleic Acids Res. 1992, 20:111-116.
58. Lasham A., Moloney S., Hale T., Homer C., Zhang Y.F., Murison J.G., Braithwaite A.W., Watson J. The Y-box-binding protein YB1, is a potential negative regulator of the p53 tumor suppressor. J. Biol. Chem. 2003, 278:35516-35523.
59. Lasham A., Print C.G., Woolley A.G., Dunn S.E., Braithwaite A.W. YB-1: oncoprotein, prognostic marker and therapeutic target?. Biochem. J. 2013, 449:11-23.
60. Lasham A., Samuel W., Cao H., Patel R., Mehta R., Stern J.L., Reid G., Woolley A.G., Miller L.D., Black M.A., Shelling A.N., Print C.G., Braithwaite A.W. YB-1, the E2F pathway, and regulation of tumor cell growth. J. Natl. Cancer Inst. 2012, 104:133-146.
61. Law J.H., Li Y., To K., Wang M., Astanehe A., Lambie K., Dhillon J., Jones S.J., Gleave M.E., Eaves C.J., Dunn S.E. Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability. PLoS ONE 2010, 5:e12661.
62. Lee C., Dhillon J., Wang M.Y., Gao Y., Hu K., Park E., Astanehe A., Hung M.C., Eirew P., Eaves C.J., Dunn S.E. Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. Cancer Res. 2008, 68:8661-8666.
63. Li Y., Wen Z.S., Yang H.X., Luo R.Z., Zhang Y., Zhang M.F., Wang X., Jia W.H. High expression of Y-box-binding protein-1 is associated with poor survival in resectable esophageal squamous cell carcinoma. Ann. Surg. Oncol. 2011, 18:3370-3376.
64. Lin L., Mernaugh R., Yi F., Blum D., Carbone D.P., Dang T.P. Targeting specific regions of the Notch3 ligand-binding domain induces apoptosis and inhibits tumor growth in lung cancer. Cancer Res. 2010, 70:632-638.
65. Lovett D.H., Cheng S., Cape L., Pollock A.S., Mertens P.R. YB-1 alters MT1-MMP trafficking and stimulates MCF-7 breast tumor invasion and metastasis. Biochem. Biophys. Res. Commun. 2010, 398:482-488.
66. Lu Z.H., Books J.T., Ley T.J. YB-1 is important for late-stage embryonic development, optimal cellular stress responses, and the prevention of premature senescence. Mol. Cell. Biol. 2005, 25:4625-4637.
67. Luo C., Tetteh P.W., Merz P.R., Dickes E., Abukiwan A., Hotz-Wagenblatt A., Holland-Cunz S., Sinnberg T., Schittek B., Schadendorf D., Diederichs S., Eichmuller S.B. miR-137 inhibits the invasion of melanoma cells through downregulation of multiple oncogenic target genes. J. Invest. Dermatol. 2013, 133:768-775.
68. Lyabin D.N., Eliseeva I.A., Ovchinnikov L.P. YB-1 protein: functions and regulation. Wiley Interdiscip. Rev. RNA 2013, 10.1002/wrna.1200.
69. Mantwill K., Naumann U., Seznec J., Girbinger V., Lage H., Surowiak P., Beier D., Mittelbronn M., Schlegel J., Holm P.S. YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells. J. Transl. Med. 2013, 11:216.
70. Meier F., Busch S., Lasithiotakis K., Kulms D., Garbe C., Maczey E., Herlyn M., Schittek B. Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br. J. Dermatol. 2007, 156:1204-1213.
71. Mertens P.R., Alfonso-Jaume M.A., Steinmann K., Lovett D.H. A synergistic interaction of transcription factors AP2 and YB-1 regulates gelatinase A enhancer-dependent transcription. J. Biol. Chem. 1998, 273:32957-32965.
72. Minich W.B., Maidebura I.P., Ovchinnikov L.P. Purification and characterization of the major 50-kDa repressor protein from cytoplasmic mRNP of rabbit reticulocytes. Eur. J. Biochem. 1993, 212:633-638.
73. Oda Y., Kohashi K., Yamamoto H., Tamiya S., Kohno K., Kuwano M., Iwamoto Y., Tajiri T., Taguchi T., Tsuneyoshi M. Different expression profiles of Y-box-binding protein-1 and multidrug resistance-associated proteins between alveolar and embryonal rhabdomyosarcoma. Cancer Sci. 2008, 99:726-732.
74. Oda Y., Ohishi Y., Basaki Y., Kobayashi H., Hirakawa T., Wake N., Ono M., Nishio K., Kuwano M., Tsuneyoshi M. Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: their correlation with activated Akt, LRP/MVP and P-glycoprotein expression. Cancer Sci. 2007, 98:1020-1026.
75. Oda Y., Ohishi Y., Saito T., Hinoshita E., Uchiumi T., Kinukawa N., Iwamoto Y., Kohno K., Kuwano M., Tsuneyoshi M. Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma. J. Pathol. 2003, 199:251-258.
76. Oda Y., Sakamoto A., Shinohara N., Ohga T., Uchiumi T., Kohno K., Tsuneyoshi M., Kuwano M., Iwamoto Y. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma. Clin. Cancer Res. 1998, 4:2273-2277.
77. Ohga T., Uchiumi T., Makino Y., Koike K., Wada M., Kuwano M., Kohno K. Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J. Biol. Chem. 1998, 273:5997-6000.
78. Okamoto T., Izumi H., Imamura T., Takano H., Ise T., Uchiumi T., Kuwano M., Kohno K. Direct interaction of p53 with the Y-box binding protein YB-1: a mechanism for regulation of human gene expression. Oncogene 2000, 19:6194-6202.
79. Panupinthu N., Yu S., Zhang D., Zhang F., Gagea M., Lu Y., Grandis J.R., Dunn S.E., Lee H.Y., Mills G.B. Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer. Oncogene 2013, 10.1038/onc.2013.1259.
80. Raffetseder U., Rauen T., Boor P., Ostendorf T., Hanssen L., Floege J., En-Nia A., Djudjaj S., Frye B.C., Mertens P.R. Extracellular YB-1 blockade in experimental nephritis upregulates Notch-3 receptor expression and signaling. Nephron Exp. Nephrol. 2011, 118:e100-e108.
81. Rauen T., Raffetseder U., Frye B.C., Djudjaj S., Muhlenberg P.J., Eitner F., Lendahl U., Bernhagen J., Dooley S., Mertens P.R. YB-1 acts as a ligand for Notch-3 receptors and modulates receptor activation. J. Biol. Chem. 2009, 284:26928-26940.
82. Reipas K.M., Law J.H., Couto N., Islam S., Li Y., Li H., Cherkasov A., Jung K., Cheema A.S., Jones S.J., Hassell J.A., Dunn S.E. Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1). Oncotarget 2013, 4:329-345.
83. Robinson D.N., Spudich J.A. Mechanics and regulation of cytokinesis. Curr. Opin. Cell Biol. 2004, 16:182-188.
84. Rognoni E., Widmaier M., Haczek C., Mantwill K., Holzmuller R., Gansbacher B., Kolk A., Schuster T., Schmid R.M., Saur D., Kaszubiak A., Lage H., Holm P.S. Adenovirus-based virotherapy enabled by cellular YB-1 expression in vitro and in vivo. Cancer Gene Ther. 2009, 16:753-763.
85. Schittek B., Psenner K., Sauer B., Meier F., Iftner T., Garbe C. The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance. Int. J. Cancer 2007, 120:2110-2118.
86. Schmid R., Meyer K., Spang R., Schittek B., Bosserhoff A.K. Melanoma inhibitory activity promotes melanoma development through activation of YBX1. Pigment Cell Melanoma Res. 2013, 26:685-696.
87. Seton-Rogers S. Therapeutics: siRNAs jump the hurdle. Nat. Rev. Cancer 2012, 12:376-377.
88. Shibahara K., Sugio K., Osaki T., Uchiumi T., Maehara Y., Kohno K., Yasumoto K., Sugimachi K., Kuwano M. Nuclear expression of the Y-box binding protein YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin. Cancer Res. 2001, 7:3151-3155.
89. Shibao K., Takano H., Nakayama Y., Okazaki K., Nagata N., Izumi H., Uchiumi T., Kuwano M., Kohno K., Itoh H. Enhanced coexpression of YB-1 and DNA topoisomerase II alpha genes in human colorectal carcinomas. Int. J. Cancer 1999, 83:732-737.
90. Shiota M., Izumi H., Onitsuka T., Miyamoto N., Kashiwagi E., Kidani A., Yokomizo A., Naito S., Kohno K. Twist promotes tumor cell growth through YB-1 expression. Cancer Res. 2008, 68:98-105.
91. Sinnberg T., Sauer B., Holm P., Spangler B., Kuphal S., Bosserhoff A., Schittek B. MAPK and PI3K/AKT mediated YB-1 activation promotes melanoma cell proliferation which is counteracted by an autoregulatory loop. Exp. Dermatol. 2012, 21:265-270.
92. Skabkin M.A., Kiselyova O.I., Chernov K.G., Sorokin A.V., Dubrovin E.V., Yaminsky I.V., Vasiliev V.D., Ovchinnikov L.P. Structural organization of mRNA complexes with major core mRNP protein YB-1. Nucleic Acids Res. 2004, 32:5621-5635.
93. Skabkina O.V., Lyabin D.N., Skabkin M.A., Ovchinnikov L.P. YB-1 autoregulates translation of its own mRNA at or prior to the step of 40S ribosomal subunit joining. Mol. Cell. Biol. 2005, 25:3317-3323.
94. Somasekharan S.P., Stoynov N., Rotblat B., Leprivier G., Galpin J.D., Ahern C.A., Foster L.J., Sorensen P.H. Identification and quantification of newly synthesized proteins translationally regulated by YB-1 using a novel Click-SILAC approach. J. Proteomics 2012, 77:e1-e10.
95. Song Y.H., Shiota M., Yokomizo A., Uchiumi T., Kiyoshima K., Kuroiwa K., Oda Y., Naito S. Twist1 and Y-box-binding protein-1 are potential prognostic factors in bladder cancer. Urol. Oncol. 2013, 10.1016/j.urolonc.2012.1011.1003.
96. Spitkovsky D.D., Royer-Pokora B., Delius H., Kisseljov F., Jenkins N.A., Gilbert D.J., Copeland N.G., Royer H.D. Tissue restricted expression and chromosomal localization of the YB-1 gene encoding a 42kD nuclear CCAAT binding protein. Nucleic Acids Res. 1992, 20:797-803.
97. Stickeler E., Fraser S.D., Honig A., Chen A.L., Berget S.M., Cooper T.A. The RNA binding protein YB-1 binds A/C-rich exon enhancers and stimulates splicing of the CD44 alternative exon v4. EMBO J. 2001, 20:3821-3830.
98. Stratford A.L., Fry C.J., Desilets C., Davies A.H., Cho Y.Y., Li Y., Dong Z., Berquin I.M., Roux P.P., Dunn S.E. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells. Breast Cancer Res. 2008, 10:R99.
99. Sutherland B.W., Kucab J., Wu J., Lee C., Cheang M.C., Yorida E., Turbin D., Dedhar S., Nelson C., Pollak M., Leighton Grimes H., Miller K., Badve S., Huntsman D., Blake-Gilks C., Chen M., Pallen C.J., Dunn S.E. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 2005, 24:4281-4292.
100. Szczuraszek K., Halon A., Materna V., Mazur G., Wrobel T., Kuliczkowski K., Donizy P., Holm P.S., Lage H., Surowiak P. Elevated YB-1 expression is a new unfavorable prognostic factor in non-Hodgkin's lymphomas. Anticancer Res. 2011, 31:2963-2970.
101. Tacke F., Kanig N., En-Nia A., Kaehne T., Eberhardt C.S., Shpacovitch V., Trautwein C., Mertens P.R. Y-box protein-1/p18 fragment identifies malignancies in patients with chronic liver disease. BMC Cancer 2011, 11:185.
102. Tay W.L., Yip G.W., Tan P.H., Matsumoto K., Yeo R., Ng T.P., Kumar S.D., Tsujimoto M., Bay B.H. Y-Box-binding protein-1 is a promising predictive marker of radioresistance and chemoradioresistance in nasopharyngeal cancer. Mod. Pathol. 2009, 22:282-290.
103. Toulany M., Schickfluss T.A., Eicheler W., Kehlbach R., Schittek B., Rodemann H.P. Impact of oncogenic K-RAS on YB-1 phosphorylation induced by ionizing radiation. Breast Cancer Res. 2011, 13:R28.
104. Uchiumi T., Fotovati A., Sasaguri T., Shibahara K., Shimada T., Fukuda T., Nakamura T., Izumi H., Tsuzuki T., Kuwano M., Kohno K. YB-1 is important for an early stage embryonic development: neural tube formation and cell proliferation. J. Biol. Chem. 2006, 281:40440-40449.
105. Uchiumi T., Kohno K., Tanimura H., Hidaka K., Asakuno K., Abe H., Uchida Y., Kuwano M. Involvement of protein kinase in environmental stress-induced activation of human multidrug resistance 1 (MDR1) gene promoter. FEBS Lett. 1993, 326:11-16.
106. Uramoto H., Izumi H., Ise T., Tada M., Uchiumi T., Kuwano M., Yasumoto K., Funa K., Kohno K. p73 interacts with c-Myc to regulate Y-box-binding protein-1 expression. J. Biol. Chem. 2002, 277:31694-31702.
107. Vaiman A.V., Stromskaya T.P., Rybalkina E.Y., Sorokin A.V., Guryanov S.G., Zabotina T.N., Mechetner E.B., Ovchinnikov L.P., Stavrovskaya A.A. Intracellular localization and content of YB-1 protein in multidrug resistant tumor cells. Biochemistry (Mosc.) 2006, 71:146-154.
108. Wachowiak R., Thieltges S., Rawnaq T., Kaifi J.T., Fiegel H., Metzger R., Quaas A., Mertens P.R., Till H., Izbicki J.R. Y-box-binding protein-1 is a potential novel tumour marker for neuroblastoma. Anticancer Res. 2010, 30:1239-1242.
109. Wei W.J., Mu S.R., Heiner M., Fu X., Cao L.J., Gong X.F., Bindereif A., Hui J. YB-1 binds to CAUC motifs and stimulates exon inclusion by enhancing the recruitment of U2AF to weak polypyrimidine tracts. Nucleic Acids Res. 2012, 40:8622-8636.
110. Wolffe A.P. Structural and functional properties of the evolutionarily ancient Y-box family of nucleic acid binding proteins. BioEssays 1994, 16:245-251.
111. Wolffe A.P., Tafuri S., Ranjan M., Familari M. The Y-box factors: a family of nucleic acid binding proteins conserved from Escherichia coli to man. New Biol. 1992, 4:290-298.
112. Woolley A.G., Algie M., Samuel W., Harfoot R., Wiles A., Hung N.A., Tan P.H., Hains P., Valova V.A., Huschtscha L., Royds J.A., Perez D., Yoon H.S., Cohen S.B., Robinson P.J., Bay B.H., Lasham A., Braithwaite A.W. Prognostic association of YB-1 expression in breast cancers: a matter of antibody. PLoS ONE 2011, 6:e20603.
113. Wu J., Lee C., Yokom D., Jiang H., Cheang M.C., Yorida E., Turbin D., Berquin I.M., Mertens P.R., Iftner T., Gilks C.B., Dunn S.E. Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res. 2006, 66:4872-4879.
114. Wu Y., Yamada S., Izumi H., Li Z., Shimajiri S., Wang K.Y., Liu Y.P., Kohno K., Sasaguri Y. Strong YB-1 expression is associated with liver metastasis progression and predicts shorter disease-free survival in advanced gastric cancer. J. Surg. Oncol. 2012, 105:724-730.
115. Xu W., Zhou L., Qin R., Tang H., Shen H. Nuclear expression of YB-1 in diffuse large B-cell lymphoma: correlation with disease activity and patient outcome. Eur. J. Haematol. 2009, 83:313-319.
116. Yasen M., Kajino K., Kano S., Tobita H., Yamamoto J., Uchiumi T., Kon S., Maeda M., Obulhasim G., Arii S., Hino O. The up-regulation of Y-box binding proteins (DNA binding protein A and Y-box binding protein-1) as prognostic markers of hepatocellular carcinoma. Clin. Cancer Res. 2005, 11:7354-7361.
117. Yoshimatsu T., Uramoto H., Oyama T., Yashima Y., Gu C., Morita M., Sugio K., Kohno K., Yasumoto K. Y-box-binding protein-1 expression is not correlated with p53 expression but with proliferating cell nuclear antigen expression in non-small cell lung cancer. Anticancer Res. 2005, 25:3437-3443.
118. Zen K., Liu D.Q., Guo Y.L., Wang C., Shan J., Fang M., Zhang C.Y., Liu Y. CD44v4 is a major E-selectin ligand that mediates breast cancer cell transendothelial migration. PLoS ONE 2008, 3:e1826.
119. Zhang Y., Reng S.R., Wang L., Lu L., Zhao Z.H., Zhang Z.K., Feng X.D., Ding X.D., Wang J., Feng G., Dai T.Z., Pu J., Du X.B. Overexpression of Y-box binding protein-1 in cervical cancer and its association with the pathological response rate to chemoradiotherapy. Med. Oncol. 2012, 29:1992-1997.
120. Zheng J., Jing W., Orentas R.J. Discovery of YB-1 as a new immunological target in neuroblastoma by vaccination in the context of regulatory T cell blockade. Acta Biochim. Biophys. Sinica 2009, 41:980-990.
121. Zheng J., Liu P., Yang X. YB-1 immunization combined with regulatory T-cell depletion induces specific T-cell responses that protect against neuroblastoma in the early stage. Acta Biochim. Biophys. Sinica 2012, 44:1006-1014.
122. Zhu X., Li Y., Shen H., Li H., Long L., Hui L., Xu W. miR-137 restoration sensitizes multidrug-resistant MCF-7/ADM cells to anticancer agents by targeting YB-1. Acta Biochim. Biophys. Sinica 2013, 45:80-86.